ClinicalTrials.gg
CompletedNCT03207750Updated Dec 29, 2020Results posted

This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine

A Phase 3 interventional study of Rotarix and Pediarix in Rotavirus Infection and Rotavirus Vaccines, sponsored by GlaxoSmithKline. Completed at 47 sites in United States. Open to participants aged 6 Weeks to 12 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-29.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,280
Allocation
Randomized
Ages
6 Weeks to 12 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 61 studies in Rotavirus Infections by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Rotavirus Infections · GlaxoSmithKline.

Enrollment
12th of 38
1,280 · median 507
Started
2017
the only one that year
Phase 3
23 of 61
none open now
Registered
60th of 61
by date

Among the 61 studies in Rotavirus Infections by GlaxoSmithKline, this one is the 12th largest by enrollment of the 38 interventional ones that give a count, is the only one that started in 2017, is one of 23 in phase 3, and was the 60th registered.

Rotavirus Infections

104 studies on the registry are indexed under Rotavirus Infections; 3 are open to participants now.

Browse Rotavirus Infections studies →

Open to participants now

None of the 61 studies in Rotavirus Infections by GlaxoSmithKline is open now. The open studies under Rotavirus Infections, anywhere →

Who these studies take

Of the 3 Rotavirus Infections studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 6 Weeks to 12 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 61 studies in Rotavirus Infections by GlaxoSmithKline as a file.
02

Study summary

The purpose of this study is to assess if there is any immune interference between the Porcine circovirus free (PCV-free) liquid Human rotavirus (HRV) vaccine and routine infant vaccinations currently in use in the US, namely Pediarix®, Hiberix® and Prevenar 13® as compared to the currently licensed lyophilized formulation of the HRV vaccine when co-administered with the same routine vaccinations in healthy infants 6-12 weeks of age

03

Conditions studied

  • Rotavirus Infection
  • Rotavirus Vaccines

Browse trials for

Keywords

  • Immunogenicity
  • lyophilized formulation
  • United States
  • Reactogenicity
  • Safety
  • Porcine circovirus -free
  • Human rotavirus vaccine
  • liquid formulation
  • Healthy infants
04

Who can participate

Ages eligible
6 Weeks to 12 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects' parent(s)/[LAR(s)] who, in the opinion of the investigator can and will comply with the requirements of the protocol.
  • A male or female between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first study vaccination.
  • Written or witnessed/thumb printed obtained from the parent(s)/LAR(s) of the subject prior to performing any study specific procedure.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion criteria

Exclusion Criteria:

  • Child in care.
  • Use of any or non-registered product other than the study vaccines during the period starting 30 days before the first dose of study vaccines (Day-29 to Day 1), or planned use during the study period.
  • Chronic administration (defined as more than 14 days in total) of or other immune-modifying drugs since birth. For , this will mean prednisone (≥0.5 mg/kg/day, or equivalent). Inhaled and topical steroids are allowed.
  • Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
  • Administration of long-acting immune-modifying drugs at any time during the study period.
  • Planned administration/administration of a vaccine not foreseen by the study protocol within the period starting 30 days before the first dose of vaccine administration and ending at Visit 4, with the exception of the inactivated influenza vaccine, which is allowed at any time during the study, if administered at a site which is different from the sites used to administer the co-administered vaccines.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.
  • Uncorrected congenital malformation of the gastrointestinal tract that would predispose for Intussusception (IS).
  • History of IS.
  • Very prematurely born infants (born ≤28 weeks of gestation).
  • Family history of congenital or hereditary immunodeficiency.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
  • Major congenital defects or serious chronic illness.
  • Previous vaccination against Haemophilus type b (Hib), diphtheria, tetanus, pertussis, pneumococcus, RV and/or poliovirus.
  • Previous confirmed occurrence of RV GE, Hib, diphtheria, tetanus, pertussis, pneumococcus, and/or polio disease.
  • Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
  • GE within 7 days preceding the study vaccine administration.
  • History of any reaction or likely to be exacerbated by any component of the vaccines.
  • Hypersensitivity to latex.
  • History of any neurological disorders or seizures.
  • History of Severe combined immunodeficiency (SCID).
  • Acute disease and/or fever at the time of enrolment.

    • Fever is defined as temperature ≥38.0°C/100.4°F. The preferred location for measuring temperature in this study will be the oral cavity, the axilla and the rectum.
    • Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
1,280 participants (actual)

Study arms

  • Experimental
    HRV PCV-free Liq Group

    Healthy female or male subjects, between and including 6 and 12 weeks (42-90 days) of age at the time of the first study vaccination who received two doses of oral live-attenuated human rotavirus (HRV) vaccine in PCV-free liquid formulation, according to a 0, 2-month schedule, co-administered with one dose of each Pediarix, Hiberix and Prevnar-13 at three timepoints (day 1, month 2 and month 4). PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.

    Biological: Rotarix · Biological: Pediarix · Biological: Hiberix · Biological: Prevenar 13

  • Active comparator
    HRV Lyo Group

    Healthy female or male subjects, between and including 6 and 12 weeks (42-90 days) of age at the time of the first study vaccination who received two doses of oral live-attenuated human rotavirus (HRV) vaccine in lyophilized formulation, according to a 0, 2-month schedule, co-administered with one dose of each Pediarix, Hiberix and Prevnar-13 at three timepoints (day 1, month 2 and month 4).

    Biological: Rotarix · Biological: Pediarix · Biological: Hiberix · Biological: Prevenar 13

Interventions

  • BiologicalRotarix

    Two doses administered orally according to a 0, 2 month schedule as per the immunization schedule for HRV vaccine administration in the US.

    Also known as: GSK Biologicals' PCV-free liquid formulation of oral live attenuated HRV vaccine., GSK Biologicals' lyophilized formulation of oral live attenuated HRV vaccine.

  • BiologicalPediarix

    Three doses administered intramuscularly according to a 0, 2, 4 month schedule.

    Also known as: GSK Biologicals' Diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated poliovirus vaccine.

  • BiologicalHiberix

    Three doses administered intramuscularly according to a 0, 2, 4 month schedule.

    Also known as: GSK Biologicals' Haemophilus b conjugate vaccine (tetanus toxoid conjugate)

  • BiologicalPrevenar 13

    Three doses administered intramuscularly according to a 0, 2, 4 month schedule.

    Also known as: Pfizer's Pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 Protein)

06

What researchers measure

Primary outcomes

  1. Number of Seroprotected Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations Above or Equal to Cut-off Value.

    Immunogenicity was assessed using Enzyme Linked Immunosorbent Assay (ELISA) in terms of seroprotection rates against diphtheria toxoid. A seroprotected subject is a subject whose antibody concentration is greater than or equal to (≥) the level defining clinical protection. The following seroprotection thresholds were applicable:anti-D antibody concentrations ≥ 0.1 International Units/milliliter (IU/mL), anti-T antibody concentrations ≥ 0.1 IU/mL.

    Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)

  2. Number of Seroprotected Subjects With Anti-hepatitis B (Anti-HBs) Antibody Concentrations Above or Equal to Cut-off Value.

    Immunogenicity was assessed using ChemiLuminescence ImmunoAssay (CLIA) in terms of seroprotection rates against Hepatitis B. A seroprotected subject is a subject whose antibody concentration is ≥ the level defining clinical protection. The following seroprotection thresholds were applicable:anti-HB antibody concentrations ≥ 10 milli International Units/milliliter (mIU/mL).

    Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)

  3. Number of Seroprotected Subjects With Anti-polio Virus Types 1, 2 and 3 Antibody Titers Above or Equal to Cut-off Value.

    Immunogenicity was assessed using virus micro-neutralization test in terms of seroprotection rates against polio virus types 1, 2 and 3. A seroprotected subject is a subject whose antibody concentration is ≥ the level defining clinical protection. The following seroprotection thresholds were applicable:anti-polio virus types 1, 2 and 3 types antibody titers ≥ 8 Estimated Dose 50% (ED50).

    Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)

  4. Immunogenicity in Terms of Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations.

    Antibody concentrations against PT, FHA and PRN were determined and expressed as Geometric Mean Concentrations (GMCs).The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations.

    Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)

  5. Immunogenicity in Terms of Anti-pneumococcal Serotypes (Anti-PnPS) Antibody Concentrations.

    Antibody concentrations against pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) were determined and expressed as GMCs in micrograms per milliliter (µg/mL).The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations.

    Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)

  6. Number of Seroprotected Subjects With Anti-polyribosyl Ribitol Phosphate (Anti-PRP) Antibody Concentrations Above or Equal to Cut-off Value of 0.15 µg/mL.

    Immunogenicity was assessed in terms of seroprotection rates against PRP antibodies. A seroprotected subject is a subject whose antibody concentration is ≥ the level defining clinical protection. The following seroprotection thresholds were applicable:anti-PRP antibody concentrations ≥ 0.15 µg/mL.

    Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)

  7. Number of Seroprotected Subjects With Anti-polyribosyl Ribitol Phosphate (Anti-PRP) Antibody Concentrations Above or Equal to Cut-off Value of 1.0 µg/mL.

    Immunogenicity was assessed in terms of seroprotection rates against PRP antibodies. A seroprotected subject is a subject whose antibody concentration is ≥ the level defining clinical protection. The following seroprotection thresholds were applicable:anti-PRP antibody concentrations ≥ 1.0 µg/mL.

    Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)

  8. Number of Subjects With Seroresponse to Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibodies.

    Seroresponse is defined as the percentage of subjects showing an antibody concentration above a threshold that leads to 95% seroresponse in the HRV lyophilized Group. The cut-offs used were as follows: anti-PT (18.566 IU/mL), anti-FHA (35.711 IU/mL) and anti-PRN (11.034 IU/mL).

    Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)

Secondary outcomes

  1. Number of Seropositive Subjects With Anti-Rota Virus Immunoglobulin A (Anti-RV IgA) Antibody Concentrations Above or Equal to Cut-off Value of 20 Units/Milliliter (U/mL).

    Immunogenicity was assessed in terms of seropositivity against Rota virus IgA antibodies. The cut off used was ≥ 20 U/mL.

    Time frame: At Month 5 (Three months after Dose 2 of HRV vaccine)

  2. Number of Seropositive Subjects With Anti-RV IgA Antibody Concentrations Above or Equal to Cut-off Value of 90 U/mL.

    Immunogenicity was assessed in terms of seropositivity against Rota virus IgA antibodies. The cut off used was ≥ 90 U/mL.

    Time frame: At Month 5 (Three months after Dose 2 of HRV vaccine)

  3. Number of Seropositive Subjects With Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations Above or Equal to Cut-off Value.

    Immunogenicity was assessed using ELISA technique in terms of seropositivity against PT, FHA and PRN antibodies. The cut-offs for antibodies were the Lower Limit Of Quantification (LLOQ) of the assays which were ≥ 2.693 IU/mL (anti-PT), ≥ 2.046 IU/mL (anti-FHA) and ≥ 2.187 IU/mL (anti-PRN). The Limit of Quantification is the lowest analyte concentration that can be quantitatively detected with a stated accuracy and precision, and LLOQ is the lowest standard curve point obtained by extrapolation, that can still be used for quantification.

    Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)

  4. Number of Seropositive Subjects With Anti-PnPS Antibody Concentrations Above or Equal to Cut-off Value.

    Immunogenicity was assessed using ELISA technique in terms of seropositivity against Pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) antibodies. The cut-off used was ≥ 0.35 µg/mL.

    Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)

  5. Immunogenicity in Terms of Anti-D and Anti-T Antibody Concentrations.

    Antibody concentrations against diphtheria and tetanus were determined and expressed as GMCs. The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations.

    Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)

  6. Immunogenicity in Terms of Anti-PRP Antibody Concentrations.

    Antibody concentrations against PRP were determined and expressed as GMCs. The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations.

    Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)

  7. Immunogenicity in Terms of Anti-HBs Antibody Concentrations.

    Antibody concentrations against Hepatitis B were determined and expressed as GMCs. The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations.

    Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)

  8. Immunogenicity in Terms of Anti-poliovirus Types 1, 2 and 3 Antibody Titers.

    Antibody concentrations against Poliovirus types 1, 2 and 3 were determined and expressed as Geometric Mean Titers (GMTs).

    Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)

  9. Number of Subjects With Any Solicited General Adverse Events (AEs).

    Assessed solicited general AEs were cough/runny nose; diarrhoea; fever measured by 3 routes which were oral, axillary and rectal, defined as temperature ≥ 38.0 degrees Celsius (°C); irritability; loss of appetite and vomiting. Any = any solicited general AE irrespective of its intensity grade and relationship to vaccination

    Time frame: During the 8-day (Days 1-8) follow-up period after each HRV vaccination.

  10. Number of Subjects With Any Unsolicited AEs.

    Unsolicited AEs assessed include any AE reported in addition to those solicited during the clinical study. Also any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms were reported as an unsolicited AE. Any= Any unsolicited AE irrespective of its intensity grade and relationship to vaccination.

    Time frame: During the 31-day (Days 1-31) follow-up period after each HRV vaccination.

  11. Number of Subjects With Any Serious Adverse Events (SAEs).

    SAEs assessed include any untoward medical occurrence that resulted in death, were life-threatening, required hospitalization or prolongation of existing hospitalization or resulted in disability/incapacity.

    Time frame: During the entire study period (Day 1 to Month 10)

07

Results

Posted Oct 31, 2019

Participant flow

The study was conducted at 48 centers in the United States (US).

Participant flow — Overall Study
MilestoneHRV Porcine Circovirus (PCV)-Free Liquid GroupHRV Lyophilized Group
Started632640
Completed574574
Not completed5866
Withdrew: Adverse event32
Withdrew: Lost to follow-up2129
Withdrew: Protocol violation01
Withdrew: Consent withdrawal, not due to an ae1113
Withdrew: Migrated / moved from the study area710
Withdrew: Not willing to participate this visit105
Withdrew: Not willing / not able to be contacted12
Withdrew: Other, not specified54

Outcome measures

PrimaryNumber of Seroprotected Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations Above or Equal to Cut-off Value.

Immunogenicity was assessed using Enzyme Linked Immunosorbent Assay (ELISA) in terms of seroprotection rates against diphtheria toxoid. A seroprotected subject is a subject whose antibody concentration is greater than or equal to (≥) the level defining clinical protection. The following seroprotection thresholds were applicable:anti-D antibody concentrations ≥ 0.1 International Units/milliliter (IU/mL), anti-T antibody concentrations ≥ 0.1 IU/mL.

Time frame:
At Month 5 (One month after Dose 3 of co-administered vaccines)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations Above or Equal to Cut-off Value.
ParticipantsHRV Porcine Circovirus (PCV)-Free Liquid GroupHRV Lyophilized Group
Anti-D478486
Anti-T486495
Statistical analysis
  • HRV Porcine Circovirus (PCV)-Free Liquid Group vs HRV Lyophilized Group · Difference in anti-d concentration: -0.00 · 95% CI -0.80 to 0.79
  • HRV Porcine Circovirus (PCV)-Free Liquid Group vs HRV Lyophilized Group · Difference in anti-t concentration: -0.00 · 95% CI -0.79 to 0.77
PrimaryNumber of Seroprotected Subjects With Anti-hepatitis B (Anti-HBs) Antibody Concentrations Above or Equal to Cut-off Value.

Immunogenicity was assessed using ChemiLuminescence ImmunoAssay (CLIA) in terms of seroprotection rates against Hepatitis B. A seroprotected subject is a subject whose antibody concentration is ≥ the level defining clinical protection. The following seroprotection thresholds were applicable:anti-HB antibody concentrations ≥ 10 milli International Units/milliliter (mIU/mL).

Time frame:
At Month 5 (One month after Dose 3 of co-administered vaccines)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects With Anti-hepatitis B (Anti-HBs) Antibody Concentrations Above or Equal to Cut-off Value.
ParticipantsHRV Porcine Circovirus (PCV)-Free Liquid GroupHRV Lyophilized Group
Number of Seroprotected Subjects With Anti-hepatitis B (Anti-HBs) Antibody Concentrations Above or Equal to Cut-off Value.457471
Statistical analysis
  • HRV Porcine Circovirus (PCV)-Free Liquid Group vs HRV Lyophilized Group · Difference in anti-hb concentration: -0.65 · 95% CI -1.90 to 0.16
PrimaryNumber of Seroprotected Subjects With Anti-polio Virus Types 1, 2 and 3 Antibody Titers Above or Equal to Cut-off Value.

Immunogenicity was assessed using virus micro-neutralization test in terms of seroprotection rates against polio virus types 1, 2 and 3. A seroprotected subject is a subject whose antibody concentration is ≥ the level defining clinical protection. The following seroprotection thresholds were applicable:anti-polio virus types 1, 2 and 3 types antibody titers ≥ 8 Estimated Dose 50% (ED50).

Time frame:
At Month 5 (One month after Dose 3 of co-administered vaccines)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects With Anti-polio Virus Types 1, 2 and 3 Antibody Titers Above or Equal to Cut-off Value.
ParticipantsHRV Porcine Circovirus (PCV)-Free Liquid GroupHRV Lyophilized Group
Anti-Polio 1477486
Anti-Polio 2463478
Anti-Polio 3439454
Statistical analysis
  • HRV Porcine Circovirus (PCV)-Free Liquid Group vs HRV Lyophilized Group · Difference in anti-polio 1 concentration: 0.21 · 95% CI -0.60 to 1.15
  • HRV Porcine Circovirus (PCV)-Free Liquid Group vs HRV Lyophilized Group · Difference in anti-polio 2 concentration: -0.01 · 95% CI -1.02 to 0.98
  • HRV Porcine Circovirus (PCV)-Free Liquid Group vs HRV Lyophilized Group · Difference in anti-polio 3 concentration: -0.00 · 95% CI -0.87 to 0.84
PrimaryImmunogenicity in Terms of Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations.

Antibody concentrations against PT, FHA and PRN were determined and expressed as Geometric Mean Concentrations (GMCs).The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations.

Time frame:
At Month 5 (One month after Dose 3 of co-administered vaccines)
Reported as:
Geometric mean · IU/mL
Immunogenicity in Terms of Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations.
IU/mLHRV Porcine Circovirus (PCV)-Free Liquid GroupHRV Lyophilized Group
Anti-PT51 (47.8 to 54.5)54.2 (51.3 to 57.4)
Anti-FHA107.3 (101.4 to 113.5)107.7 (101.6 to 114.1)
Anti-PRN55 (50.1 to 60.4)56.6 (51.9 to 61.7)
Statistical analysis
  • HRV Porcine Circovirus (PCV)-Free Liquid Group vs HRV Lyophilized Group · ANOVA · Gmc ratio: 0.94 · 95% CI 0.86 to 1.03ANOVA model that included the vaccine group as fixed effect.
  • HRV Porcine Circovirus (PCV)-Free Liquid Group vs HRV Lyophilized Group · ANOVA · Gmc ratio: 1.00 · 95% CI 0.92 to 1.08ANOVA model that included the vaccine group as fixed effect.
  • HRV Porcine Circovirus (PCV)-Free Liquid Group vs HRV Lyophilized Group · ANOVA · Gmc ratio: 0.97 · 95% CI 0.86 to 1.10ANOVA model that included the vaccine group as fixed effect.
PrimaryImmunogenicity in Terms of Anti-pneumococcal Serotypes (Anti-PnPS) Antibody Concentrations.

Antibody concentrations against pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) were determined and expressed as GMCs in micrograms per milliliter (µg/mL).The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations.

Time frame:
At Month 5 (One month after Dose 3 of co-administered vaccines)
Reported as:
Geometric mean · µg/mL
Immunogenicity in Terms of Anti-pneumococcal Serotypes (Anti-PnPS) Antibody Concentrations.
µg/mLHRV Porcine Circovirus (PCV)-Free Liquid GroupHRV Lyophilized Group
Anti-PnPS 11.95 (1.81 to 2.10)1.89 (1.76 to 2.03)
Anti-PnPS 30.53 (0.49 to 0.57)0.53 (0.49 to 0.57)
Anti-PnPS 41.24 (1.16 to 1.34)1.25 (1.18 to 1.34)
Anti-PnPS 51.28 (1.17 to 1.39)1.22 (1.13 to 1.31)
Anti-PnPS 6A2.84 (2.64 to 3.05)2.8 (2.61 to 3.00)
Anti-PnPS 6B1.93 (1.72 to 2.15)2 (1.80 to 2.22)
Anti-PnPS 7F3.01 (2.83 to 3.21)3.04 (2.86 to 3.22)
Anti-PnPS 9V1.68 (1.56 to 1.81)1.63 (1.52 to 1.75)
Anti-PnPS 146.27 (5.74 to 6.84)6.26 (5.75 to 6.82)
Anti-PnPS 18C1.81 (1.68 to 1.95)1.76 (1.64 to 1.89)
Anti-PnPS 19A1.87 (1.73 to 2.02)1.8 (1.68 to 1.93)
Anti-PnPS 19F2.94 (2.76 to 3.12)2.85 (2.69 to 3.03)
Anti-PnPS 23F1.14 (1.04 to 1.24)1.16 (1.07 to 1.26)
Statistical analysis
  • HRV Porcine Circovirus (PCV)-Free Liquid Group vs HRV Lyophilized Group · ANOVA · Gmc ratio: 1.03 · 95% CI 0.93 to 1.14ANOVA model that included the vaccine group as fixed effect.
  • HRV Porcine Circovirus (PCV)-Free Liquid Group vs HRV Lyophilized Group · ANOVA · Gmc ratio: 1.00 · 95% CI 0.91 to 1.11ANOVA model that included the vaccine group as fixed effect.
  • HRV Porcine Circovirus (PCV)-Free Liquid Group vs HRV Lyophilized Group · ANOVA · Gmc ratio: 0.99 · 95% CI 0.90 to 1.09ANOVA model that included the vaccine group as fixed effect.
  • HRV Porcine Circovirus (PCV)-Free Liquid Group vs HRV Lyophilized Group · ANOVA · Gmc ratio: 1.05 · 95% CI 0.94 to 1.17ANOVA model that included the vaccine group as fixed effect.
  • HRV Porcine Circovirus (PCV)-Free Liquid Group vs HRV Lyophilized Group · ANOVA · Gmc ratio: 1.01 · 95% CI 0.92 to 1.12ANOVA model that included the vaccine group as fixed effect.
  • HRV Porcine Circovirus (PCV)-Free Liquid Group vs HRV Lyophilized Group · ANOVA · Gmc ratio: 0.96 · 95% CI 0.83 to 1.12ANOVA model that included the vaccine group as fixed effect.
  • HRV Porcine Circovirus (PCV)-Free Liquid Group vs HRV Lyophilized Group · ANOVA · Gmc ratio: 0.99 · 95% CI 0.91 to 1.08ANOVA model that included the vaccine group as fixed effect.
  • HRV Porcine Circovirus (PCV)-Free Liquid Group vs HRV Lyophilized Group · ANOVA · Gmc ratio: 1.03 · 95% CI 0.93 to 1.14ANOVA model that included the vaccine group as fixed effect.
  • HRV Porcine Circovirus (PCV)-Free Liquid Group vs HRV Lyophilized Group · ANOVA · Gmc ratio: 1.00 · 95% CI 0.89 to 1.13ANOVA model that included the vaccine group as fixed effect.
  • HRV Porcine Circovirus (PCV)-Free Liquid Group vs HRV Lyophilized Group · ANOVA · Gmc ratio: 1.03 · 95% CI 0.92 to 1.14ANOVA model that included the vaccine group as fixed effect.
  • HRV Porcine Circovirus (PCV)-Free Liquid Group vs HRV Lyophilized Group · ANOVA · Gmc ratio: 1.04 · 95% CI 0.93 to 1.15ANOVA model that included the vaccine group as fixed effect.
  • HRV Porcine Circovirus (PCV)-Free Liquid Group vs HRV Lyophilized Group · ANOVA · Gmc ratio: 1.03 · 95% CI 0.95 to 1.12ANOVA model that included the vaccine group as fixed effect.
  • HRV Porcine Circovirus (PCV)-Free Liquid Group vs HRV Lyophilized Group · ANOVA · Gmc ratio: 0.98 · 95% CI 0.87 to 1.10ANOVA model that included the vaccine group as fixed effect.
PrimaryNumber of Seroprotected Subjects With Anti-polyribosyl Ribitol Phosphate (Anti-PRP) Antibody Concentrations Above or Equal to Cut-off Value of 0.15 µg/mL.

Immunogenicity was assessed in terms of seroprotection rates against PRP antibodies. A seroprotected subject is a subject whose antibody concentration is ≥ the level defining clinical protection. The following seroprotection thresholds were applicable:anti-PRP antibody concentrations ≥ 0.15 µg/mL.

Time frame:
At Month 5 (One month after Dose 3 of co-administered vaccines)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects With Anti-polyribosyl Ribitol Phosphate (Anti-PRP) Antibody Concentrations Above or Equal to Cut-off Value of 0.15 µg/mL.
ParticipantsHRV Porcine Circovirus (PCV)-Free Liquid GroupHRV Lyophilized Group
Number of Seroprotected Subjects With Anti-polyribosyl Ribitol Phosphate (Anti-PRP) Antibody Concentrations Above or Equal to Cut-off Value of 0.15 µg/mL.473479
Statistical analysis
  • HRV Porcine Circovirus (PCV)-Free Liquid Group vs HRV Lyophilized Group · Difference in anti-prp concentration: 0.17 · 95% CI -1.94 to 2.28
PrimaryNumber of Seroprotected Subjects With Anti-polyribosyl Ribitol Phosphate (Anti-PRP) Antibody Concentrations Above or Equal to Cut-off Value of 1.0 µg/mL.

Immunogenicity was assessed in terms of seroprotection rates against PRP antibodies. A seroprotected subject is a subject whose antibody concentration is ≥ the level defining clinical protection. The following seroprotection thresholds were applicable:anti-PRP antibody concentrations ≥ 1.0 µg/mL.

Time frame:
At Month 5 (One month after Dose 3 of co-administered vaccines)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects With Anti-polyribosyl Ribitol Phosphate (Anti-PRP) Antibody Concentrations Above or Equal to Cut-off Value of 1.0 µg/mL.
ParticipantsHRV Porcine Circovirus (PCV)-Free Liquid GroupHRV Lyophilized Group
Number of Seroprotected Subjects With Anti-polyribosyl Ribitol Phosphate (Anti-PRP) Antibody Concentrations Above or Equal to Cut-off Value of 1.0 µg/mL.394404
Statistical analysis
  • HRV Porcine Circovirus (PCV)-Free Liquid Group vs HRV Lyophilized Group · Difference in anti-prp concentration: -0.88 · 95% CI -5.75 to 3.99
PrimaryNumber of Subjects With Seroresponse to Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibodies.

Seroresponse is defined as the percentage of subjects showing an antibody concentration above a threshold that leads to 95% seroresponse in the HRV lyophilized Group. The cut-offs used were as follows: anti-PT (18.566 IU/mL), anti-FHA (35.711 IU/mL) and anti-PRN (11.034 IU/mL).

Time frame:
At Month 5 (One month after Dose 3 of co-administered vaccines)
Reported as:
Count of participants · Participants
Number of Subjects With Seroresponse to Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibodies.
ParticipantsHRV Porcine Circovirus (PCV)-Free Liquid GroupHRV Lyophilized Group
Anti-PT440470
Anti-FHA466470
Anti-PRN455470
Statistical analysis
  • HRV Porcine Circovirus (PCV)-Free Liquid Group vs HRV Lyophilized Group · t-test, 1 sided · p = <.0001p-value was computed by integrating on p-values of 1 sided test with alpha=0.025 \& the posterior probability of the cut-off in HRV Lyophilized group
  • HRV Porcine Circovirus (PCV)-Free Liquid Group vs HRV Lyophilized Group · t-test, 1 sided · p = <.0001p-value was computed by integrating on p-values of 1 sided test with alpha=0.025 \& the posterior probability of the cut-off in HRV lyophilized group
  • HRV Porcine Circovirus (PCV)-Free Liquid Group vs HRV Lyophilized Group · t-test, 1 sided · p = <.0001p-value was computed by integrating on p-values of 1 sided test with alpha=0.025 \& the posterior probability of the cut-off in HRV Lyophilized group
SecondaryNumber of Seropositive Subjects With Anti-Rota Virus Immunoglobulin A (Anti-RV IgA) Antibody Concentrations Above or Equal to Cut-off Value of 20 Units/Milliliter (U/mL).

Immunogenicity was assessed in terms of seropositivity against Rota virus IgA antibodies. The cut off used was ≥ 20 U/mL.

Time frame:
At Month 5 (Three months after Dose 2 of HRV vaccine)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects With Anti-Rota Virus Immunoglobulin A (Anti-RV IgA) Antibody Concentrations Above or Equal to Cut-off Value of 20 Units/Milliliter (U/mL).
ParticipantsHRV Porcine Circovirus (PCV)-Free Liquid GroupHRV Lyophilized Group
Number of Seropositive Subjects With Anti-Rota Virus Immunoglobulin A (Anti-RV IgA) Antibody Concentrations Above or Equal to Cut-off Value of 20 Units/Milliliter (U/mL).318336
SecondaryNumber of Seropositive Subjects With Anti-RV IgA Antibody Concentrations Above or Equal to Cut-off Value of 90 U/mL.

Immunogenicity was assessed in terms of seropositivity against Rota virus IgA antibodies. The cut off used was ≥ 90 U/mL.

Time frame:
At Month 5 (Three months after Dose 2 of HRV vaccine)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects With Anti-RV IgA Antibody Concentrations Above or Equal to Cut-off Value of 90 U/mL.
ParticipantsHRV Porcine Circovirus (PCV)-Free Liquid GroupHRV Lyophilized Group
Number of Seropositive Subjects With Anti-RV IgA Antibody Concentrations Above or Equal to Cut-off Value of 90 U/mL.219238
SecondaryNumber of Seropositive Subjects With Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations Above or Equal to Cut-off Value.

Immunogenicity was assessed using ELISA technique in terms of seropositivity against PT, FHA and PRN antibodies. The cut-offs for antibodies were the Lower Limit Of Quantification (LLOQ) of the assays which were ≥ 2.693 IU/mL (anti-PT), ≥ 2.046 IU/mL (anti-FHA) and ≥ 2.187 IU/mL (anti-PRN). The Limit of Quantification is the lowest analyte concentration that can be quantitatively detected with a stated accuracy and precision, and LLOQ is the lowest standard curve point obtained by extrapolation, that can still be used for quantification.

Time frame:
At Month 5 (One month after Dose 3 of co-administered vaccines)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects With Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations Above or Equal to Cut-off Value.
ParticipantsHRV Porcine Circovirus (PCV)-Free Liquid GroupHRV Lyophilized Group
Anti-PT485495
Anti-FHA486495
Anti-PRN486495
SecondaryNumber of Seropositive Subjects With Anti-PnPS Antibody Concentrations Above or Equal to Cut-off Value.

Immunogenicity was assessed using ELISA technique in terms of seropositivity against Pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) antibodies. The cut-off used was ≥ 0.35 µg/mL.

Time frame:
At Month 5 (One month after Dose 3 of co-administered vaccines)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects With Anti-PnPS Antibody Concentrations Above or Equal to Cut-off Value.
ParticipantsHRV Porcine Circovirus (PCV)-Free Liquid GroupHRV Lyophilized Group
Anti-PnPS 1442463
Anti-PnPS 3317322
Anti-PnPS 4434453
Anti-PnPS 5409424
Anti-PnPS 6A441461
Anti-PnPS 6B407434
Anti-PnPS 7F448466
Anti-PnPS 9V431454
Anti-PnPS 14441454
Anti-PnPS 18C436451
Anti-PnPS 19A438458
Anti-PnPS 19F448465
Anti-PnPS 23F409425
SecondaryImmunogenicity in Terms of Anti-D and Anti-T Antibody Concentrations.

Antibody concentrations against diphtheria and tetanus were determined and expressed as GMCs. The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations.

Time frame:
At Month 5 (One month after Dose 3 of co-administered vaccines)
Reported as:
Geometric mean · IU/mL
Immunogenicity in Terms of Anti-D and Anti-T Antibody Concentrations.
IU/mLHRV Porcine Circovirus (PCV)-Free Liquid GroupHRV Lyophilized Group
Anti-D1.85 (1.72 to 1.98)1.88 (1.75 to 2.02)
Anti-T1.88 (1.75 to 2.02)1.86 (1.74 to 1.99)
SecondaryImmunogenicity in Terms of Anti-PRP Antibody Concentrations.

Antibody concentrations against PRP were determined and expressed as GMCs. The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations.

Time frame:
At Month 5 (One month after Dose 3 of co-administered vaccines)
Reported as:
Geometric mean · µg/mL
Immunogenicity in Terms of Anti-PRP Antibody Concentrations.
µg/mLHRV Porcine Circovirus (PCV)-Free Liquid GroupHRV Lyophilized Group
Immunogenicity in Terms of Anti-PRP Antibody Concentrations.4.41 (3.82 to 5.09)4.28 (3.71 to 4.94)
SecondaryImmunogenicity in Terms of Anti-HBs Antibody Concentrations.

Antibody concentrations against Hepatitis B were determined and expressed as GMCs. The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations.

Time frame:
At Month 5 (One month after Dose 3 of co-administered vaccines)
Reported as:
Geometric mean · mIU/mL
Immunogenicity in Terms of Anti-HBs Antibody Concentrations.
mIU/mLHRV Porcine Circovirus (PCV)-Free Liquid GroupHRV Lyophilized Group
Immunogenicity in Terms of Anti-HBs Antibody Concentrations.2031.3 (1834.6 to 2249.0)2168.9 (1977.5 to 2378.9)
SecondaryImmunogenicity in Terms of Anti-poliovirus Types 1, 2 and 3 Antibody Titers.

Antibody concentrations against Poliovirus types 1, 2 and 3 were determined and expressed as Geometric Mean Titers (GMTs).

Time frame:
At Month 5 (One month after Dose 3 of co-administered vaccines)
Reported as:
Geometric mean · Titers
Immunogenicity in Terms of Anti-poliovirus Types 1, 2 and 3 Antibody Titers.
TitersHRV Porcine Circovirus (PCV)-Free Liquid GroupHRV Lyophilized Group
Anti-Polio 1747.2 (673.5 to 828.8)728.2 (656.3 to 808.0)
Anti-Polio 2659.6 (587.9 to 740.0)699.3 (627.7 to 779.0)
Anti-Polio 31228.7 (1100.3 to 1372.1)1291.6 (1159.1 to 1439.3)
SecondaryNumber of Subjects With Any Solicited General Adverse Events (AEs).

Assessed solicited general AEs were cough/runny nose; diarrhoea; fever measured by 3 routes which were oral, axillary and rectal, defined as temperature ≥ 38.0 degrees Celsius (°C); irritability; loss of appetite and vomiting. Any = any solicited general AE irrespective of its intensity grade and relationship to vaccination

Time frame:
During the 8-day (Days 1-8) follow-up period after each HRV vaccination.
Reported as:
Count of participants · Participants
Number of Subjects With Any Solicited General Adverse Events (AEs).
ParticipantsHRV Porcine Circovirus (PCV)-Free Liquid GroupHRV Lyophilized Group
Cough / Runny Nose (Dose 1), Any172180
Cough / Runny Nose (Dose 2), Any224222
Cough / Runny Nose (Across doses), Any305313
Diarrhea (Dose 1), Any3936
Diarrhea (Dose 2), Any3426
Diarrhea (Across doses), Any6955
Fever (Dose 1), ≥ 38.0°C3632
Fever (Dose 2), ≥ 38.0°C6475
Fever (Across doses), ≥ 38.0°C8995
Irritability / Fussiness (Dose 1), Any448458
Irritability / Fussiness (Dose 2), Any440427
Irritability / Fussiness (Across doses), Any523522
Loss of appetite (Dose 1), Any204214
Loss of appetite (Dose 2), Any179178
Loss of appetite (Across doses), Any292293
Vomiting (Dose 1), Any110105
Vomiting (Dose 2), Any8378
Vomiting (Across doses), Any147148
SecondaryNumber of Subjects With Any Unsolicited AEs.

Unsolicited AEs assessed include any AE reported in addition to those solicited during the clinical study. Also any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms were reported as an unsolicited AE. Any= Any unsolicited AE irrespective of its intensity grade and relationship to vaccination.

Time frame:
During the 31-day (Days 1-31) follow-up period after each HRV vaccination.
Reported as:
Count of participants · Participants
Number of Subjects With Any Unsolicited AEs.
ParticipantsHRV Porcine Circovirus (PCV)-Free Liquid GroupHRV Lyophilized Group
Number of Subjects With Any Unsolicited AEs.294327
SecondaryNumber of Subjects With Any Serious Adverse Events (SAEs).

SAEs assessed include any untoward medical occurrence that resulted in death, were life-threatening, required hospitalization or prolongation of existing hospitalization or resulted in disability/incapacity.

Time frame:
During the entire study period (Day 1 to Month 10)
Reported as:
Count of participants · Participants
Number of Subjects With Any Serious Adverse Events (SAEs).
ParticipantsHRV Porcine Circovirus (PCV)-Free Liquid GroupHRV Lyophilized Group
Number of Subjects With Any Serious Adverse Events (SAEs).2019

Adverse events

Collected over Solicited AEs: During the 8-day (Day 1 to Day 8) follow-up period after each HRV vaccination. Unsolicited AEs: During the 31-day (Day 1 to Day 31) follow-up period after each HRV vaccination. SAEs: Throughout the study period (Day 1 to Month 10).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HRV Porcine Circovirus (PCV)-Free Liquid Group1/632 (0.2%)20/632 (3.2%)571/632 (90.3%)
HRV Lyophilized Group0/640 (0%)19/640 (3%)589/640 (92%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventHRV Porcine Circovirus (PCV)-Free Liquid GroupHRV Lyophilized Group
BronchiolitisInfections and infestations5/6324/640
Respiratory syncytial virus bronchiolitisInfections and infestations3/6324/640
DehydrationMetabolism and nutrition disorders2/6321/640
PneumoniaInfections and infestations2/6321/640
PyelonephritisInfections and infestations2/6320/640
Respiratory distressRespiratory, thoracic and mediastinal disorders2/6321/640
Rhinovirus infectionInfections and infestations2/6321/640
SeizureNervous system disorders2/6320/640
Adenovirus infectionInfections and infestations0/6322/640
Blood glucose abnormalInvestigations1/6320/640
Most frequent other events
Showing 10 of 205
Most frequent other events
EventHRV Porcine Circovirus (PCV)-Free Liquid GroupHRV Lyophilized Group
IrritabilityPsychiatric disorders523/632522/640
CoughRespiratory, thoracic and mediastinal disorders320/632330/640
Decreased appetiteMetabolism and nutrition disorders293/632293/640
VomitingGastrointestinal disorders155/632156/640
DiarrhoeaGastrointestinal disorders126/632113/640
PyrexiaGeneral disorders102/632116/640
Upper respiratory tract infectionInfections and infestations63/63269/640
Nasal congestionRespiratory, thoracic and mediastinal disorders28/63240/640
Otitis mediaInfections and infestations26/63223/640
Otitis media acuteInfections and infestations14/63223/640

Baseline characteristics

Age, Continuous
Age, Continuous(Weeks)HRV Porcine Circovirus (PCV)-Free Liquid GroupHRV Lyophilized GroupTotal
Mean8.7 ± 1.18.7 ± 1.18.7 ± 1.1
Sex: Female, Male
Sex: Female, Male(Participants)HRV Porcine Circovirus (PCV)-Free Liquid GroupHRV Lyophilized GroupTotal
Female308309617
Male324331655
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)HRV Porcine Circovirus (PCV)-Free Liquid GroupHRV Lyophilized GroupTotal
American Indian Or Alaska Native8715
Asian202242
Black Or African American7478152
Native Hawaiian Or Other Pacific Islander224
White468471939
Other, not specified6060120
08

Study locations

47 sites
  • GSK Investigational Site
    Birmingham, Alabama 35205, United States
  • GSK Investigational Site
    Fayetteville, Arkansas 72703, United States
  • GSK Investigational Site
    Jonesboro, Arkansas 72401, United States
  • GSK Investigational Site
    Daly City, California 94015, United States
  • GSK Investigational Site
    Oakland, California 94611, United States
  • GSK Investigational Site
    Walnut Creek, California 94596, United States
  • GSK Investigational Site
    West Covina, California 91790, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80922, United States
  • GSK Investigational Site
    Altamonte Springs, Florida 32701, United States
  • GSK Investigational Site
    Boynton Beach, Florida 33435, United States
  • GSK Investigational Site
    Miami, Florida 33142, United States
  • GSK Investigational Site
    Tampa, Florida 33617, United States
  • GSK Investigational Site
    Nampa, Idaho 83686, United States
  • GSK Investigational Site
    Bardstown, Kentucky 40004, United States
  • GSK Investigational Site
    Louisville, Kentucky 40202, United States
  • GSK Investigational Site
    Frederick, Maryland 21702, United States
  • GSK Investigational Site
    Fall River, Massachusetts 02721, United States
  • GSK Investigational Site
    Bingham Farms, Michigan 48025, United States
  • GSK Investigational Site
    Lincoln, Nebraska 68504, United States
  • GSK Investigational Site
    Lincoln, Nebraska 68505, United States
  • GSK Investigational Site
    Lincoln, Nebraska 68522, United States
  • GSK Investigational Site
    Bronx, New York 10468, United States
  • GSK Investigational Site
    Syracuse, New York 13202, United States
  • GSK Investigational Site
    Boone, North Carolina 28607, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27609, United States
  • GSK Investigational Site
    Cleveland, Ohio 44121, United States
  • GSK Investigational Site
    Dayton, Ohio 45406, United States
  • GSK Investigational Site
    Dayton, Ohio 45414, United States
  • GSK Investigational Site
    Dayton, Ohio 45419, United States
  • GSK Investigational Site
    Grove City, Ohio 43123, United States
  • GSK Investigational Site
    Hermitage, Pennsylvania 16148, United States
  • GSK Investigational Site
    Charleston, South Carolina 29407, United States
  • GSK Investigational Site
    North Charleston, South Carolina 29406-9170, United States
  • GSK Investigational Site
    Kingsport, Tennessee 37660, United States
  • GSK Investigational Site
    Fort Worth, Texas 76107, United States
  • GSK Investigational Site
    Galveston, Texas 77555, United States
  • GSK Investigational Site
    Tomball, Texas 77375, United States
  • GSK Investigational Site
    Kaysville, Utah 84037, United States
  • GSK Investigational Site
    Layton, Utah 84041, United States
  • GSK Investigational Site
    Murray, Utah 84107, United States
  • GSK Investigational Site
    Orem, Utah 84057, United States
  • GSK Investigational Site
    Provo, Utah 84604, United States
  • GSK Investigational Site
    Roy, Utah 84067, United States
  • GSK Investigational Site
    South Jordan, Utah 84095, United States
  • GSK Investigational Site
    Syracuse, Utah 84075, United States
  • GSK Investigational Site
    Charlottesville, Virginia 22902, United States
  • GSK Investigational Site
    Marshfield, Wisconsin 54449, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study is available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (copy the URL below to your browser)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Oct 2018, 12 months.

Results were first posted in Oct 2019, 1 year after primary completion.

Of 14 phase 3 interventional studies under Rotavirus Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 12 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2017
First posted
Jul 5, 2017
StartActual
Sep 14, 2017
Primary completionActual
Oct 9, 2018
CompletionActual
Mar 1, 2019
Results first posted
Oct 31, 2019
Last update
Dec 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03207750
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 5, 2017
Start date
Sep 14, 2017
Primary completion
Oct 9, 2018
Completion
Mar 1, 2019
Results posted
Oct 31, 2019
Last update
Dec 29, 2020

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pediarix · Hiberix · 13-valent pneumococcal vaccine

Start the discussion